More Articles

Ranbaxy forfeits exclusivity on generic Provigil Generics/News | Posted 17/08/2012

As part of Ranbaxy’s consent decree with FDA, signed in January 2012, the Indian generics major had to agree to relinquish 180-day marketing exclusivity on three pending generic drug applications [...

Patient power predominates at DIA Europe’s Clinical Forum Conferences | Posted 17/08/2012

DIA Europe’s 2012 Clinical Forum in October this year promises to be an important multidisciplinary conference for all engaged in the clinical development and therapeutic use of medicines. The them...

Generics saved US healthcare system and patients US$1 trillion Reports | Posted 10/08/2012

According to a new report from the Generic Pharmaceutical Association (GPhA), released on 2 August 2012, generics saved the US healthcare system and patients US$1 billion every other day―totaling U...

Testing for unwanted immunogenicity from biologicals Biosimilars/Research | Posted 10/08/2012

Immunogenicity caused by biologicals, both originator and biosimilar, is an important issue that was raised by Dr Wadhwa from the National Institute for Biological Standards and Control [1].

Canada grapples with drugs costs Generics/General | Posted 10/08/2012

Government report calls for the widening of the current scheme for brand-name medicines to include generics.

Rising tensions over drug pricing and patenting in India Policies & Legislation | Posted 10/08/2012

New developments in pricing and regulations of drugs in India mean that tensions are likely to mount over the coming months between international pharmaceutical interests and healthcare providers w...

Generics makers Sun and Stada considering deal Pharma News | Posted 10/08/2012

Rumours are that Indian-based generics manufacturer Sun Pharma and Germany’s generics maker Stada Arzneimittel (Stada) may be looking at a deal in the near future, although both sides deny or refus...

Asian companies venture into biosimilars for kidney failure Biosimilars/News | Posted 10/08/2012

Malaysia-based Chemical Company of Malaysia Berhad (CCM) wholly-owned subsidiary CCM Duopharma Biotech Berhad and Korea-based biotechnology company PanGen Biotech announced on 19 June 2012 that the...